The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

25 Jan 2021 07:00

RNS Number : 6804M
Sopheon PLC
25 January 2021
 

Embargoed release: 07:00hrs Monday 25 January 2021

 

 

 

SOPHEON PLC

("Sopheon", the "Company" or the "Group")

 

TRADING UPDATE

 

Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, provides the following trading update for the year ended 31 December 2020.

 

As in prior years, the final quarter was the strongest of the year for the Group, and in fact stronger than 2019, despite the resurgence of Covid concerns globally. We are pleased to report ongoing commercial traction and material progress in two strategic areas of focus: migration to a Software as a Service ("SaaS") recurring revenue model - giving both enhanced revenue visibility to future periods and improved quality of earnings - and landing large enterprise class contracts with major companies.

 

Total contract value ("TCV") of signed SaaS business grew 274% year on year, due to rapid adoption by our sales teams of the SaaS model for new customers, as well as converting some existing perpetual customers. Annual Recurring Revenue ("ARR") gross retention for the year remained respectable, at 91.5% (2019: 94.2%) but this represented greater than normal attrition, which is unsurprising given the challenging market conditions for some customers last year. Overall, the TCV of all sales bookings increased by 23% year on year, but the shift of emphasis from perpetual to multi-year SaaS means that most of this revenue will be recognized over time, rather than in the year of sale. New wins included global brands such as DuPont and LG, alongside previously announced Mondelēz and Orion. Six of our new customers had initial deal value at $1m or more, compared to just one in 2019, underlining material traction with enterprise sales even in these difficult times.

 

We expect that revenue for the year ended 31 December 2020 will be approximately $30m, in line with our 2019 performance. ARR is expected to rise to $18m (2019: $15.9m). This, coupled with a substantial order book of services, means that revenue visibility1 for 2021 is already at $22m (2019: $18.9m) giving cause for optimism regarding the year ahead.

 

Adjusted EBITDA is expected to be in the region of $5.6m (2019: $6.4m). Net cash on 31 December 2020 was $21.6m (2019: $19.4m), demonstrating the cash generative nature of the business as well as the robust balance sheet. As noted previously, billing seasonality means that this number should rise in the early part of 2021. In addition, costs reflect initial investments in a native cloud platform to enable new SaaS products, that will take us into new market segments. This was in parallel with further investments in our enterprise Accolade platform. These initiatives will continue in 2021.

 

Financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. In line with our normal reporting schedule, Sopheon plans to issue its results for the year ended 31 December 2020 on 24 March 2021.

 

Sopheon's Chairman, Barry Mence said: "I'm very proud that Sopheon has been able to match prior year revenue and grow total sales bookings in such a difficult global climate. We've done this while simultaneously embarking on a migration of our business from up-front perpetual license sales to a SaaS subscription model - leading to a solid increase in recurring revenues, and providing greater visibility to future years. We believe we have a substantial opportunity ahead of us, and our strong balance sheet gives us the confidence to maintain ambitious investment plans through the pandemic and beyond."

 

 

For further information contact:

Barry Mence (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Giles Rolls (Corporate Finance)Alice Lane / Sunila de Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

1 Revenue visibility is defined on page 7 of Sopheon's 2019 annual report which is available from the investor section of www.sopheon.com.

 

The information communicated in this announcement is inside information

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZLFLFFLBBBQ
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.